Expression of Na-K-Cl cotransporter and edema formation are age dependent after ischemic stroke.

Age is the most important independent risk factor for stroke; however aging animals are rarely used in stroke studies. Previous work demonstrated that young male mice had more edema formation after an induced stroke than aging animals. An important contributor to cerebral edema formation is the Na-K-Cl cotransporter (NKCC). We examined the expression of NKCC in young (10-12 weeks) and aging (15-16 months) C57BL6 male mice after middle cerebral artery occlusion (MCAO) and investigated the effect of pharmacological inhibition of NKCC with Bumetanide on cerebral edema formation. Both immunofluorescent staining and Western blotting analysis showed that NKCC expression was significantly higher in the ischemic penumbra of young compared to aging mice after stroke. Edema formation was significantly more robust in young mice and was reduced with Bumetanide. Bumetanide had no effect on cerebral edema in aging mice after MCAO. This suggests that NKCC expression and edema formation are age dependent after ischemic stroke.
AuthorsFudong Liu, Padmastuti Akella, Sharon E Benashski, Yan Xu, Louise D McCullough
JournalExperimental neurology (Exp Neurol) Vol. 224 Issue 2 Pg. 356-61 (Aug 2010) ISSN: 1090-2430 [Electronic] United States
PMID20406636 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright(c) 2010 Elsevier Inc. All rights reserved.
Chemical References
  • Sodium Potassium Chloride Symporter Inhibitors
  • Sodium-Potassium-Chloride Symporters
  • Bumetanide
  • Aging (physiology)
  • Animals
  • Brain (metabolism)
  • Brain Edema (etiology, metabolism, prevention & control)
  • Bumetanide (therapeutic use)
  • Infarction, Middle Cerebral Artery (complications)
  • Ischemic Attack, Transient (complications, metabolism, prevention & control)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Sodium Potassium Chloride Symporter Inhibitors (therapeutic use)
  • Sodium-Potassium-Chloride Symporters (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: